Thus, a large amount of investigations on BC have been focused on the identification of promising molecular biomarkers that could precisely evaluate patients' progression risk and help clinicians to optimize individual therapeutic strategy.3 For instance, we previously demonstrated that high expression of Rab25 is associated with lymph node metastasis and inferior clinical outcome of BC patients.4 To date, however, the search for specific biomarkers in BC cells that have clinical/prognostic value is still substantially limited. The gene discussed is RAB25; the disease is breast cancer.